Revenue and EBITDA from the Teva portfolio came in below expectations. Other aspects of the business seem to be performing as expected. Key to any recovery would be Mayne's ability to diversify its channels to market, and pursue new market share opportunities.
A couple of analysts have released new targets since the market update.
- UBS reduced theirs to $1.70.
- Morningstar left theirs at $1.70. This was because the effective tax rate was 27%, compared to the forecast of 32%, leaving NPAT close to their forecast. Presumably the lower tax rate resulted from the intangible asset impairment and reassessment of the useful life of the acquired Teva portfolio.
Analyst price targets after market update
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.89 |
Change
-0.410(7.74%) |
Mkt cap ! $416.0M | |||
| Open | High | Low | Value | Volume |
| $5.30 | $5.30 | $4.84 | $1.003M | 199.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1026 | $4.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.91 | 1675 | 1 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| MYX (ASX) Chart |